Drug tech firm Alkermes bullish despite reporting full-year loss
Company drops development of new pain therapy after missing targets in Phase 1 trial
Alkermes shares surge as trials prove potential for new schizophrenia drug
Company will seek US marketing approval for long-acting injectible aripiprazole lauroxil
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices